Brought to you by 
Roche licenses IPF candidate to Ark Biosciences
Sep 2018
Executive Summary
Roche’s Genentech Inc. licensed Ark Biosciences Inc. exclusive worldwide development and commercialization rights to its Phase I idiopathic pulmonary fibrosis (IPF) program AK3280 (GDC3280) plus related compounds.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Reverse Licensing
- R+D and Marketing-Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com